Cationic Lipid S104 Synthesis With High Yield and Low By-Products
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthetic processes for producing cationic lipids like S104 suffer from low yield, inconvenient work-up procedures, and high levels of side products, making them inefficient and costly.
Innovation Solution
A multi-step process involving the reaction of compounds of specific formulas with protecting groups, halogens, and bases, followed by treatments with methane sulfonic acid and oxalic acid, to produce cationic lipid S104 with high yield and low by-product concentration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If previous synthetic strategies for producing S104 are used, then the cationic lipid can be produced, but the yield is low and by-product formation is high
Solution Approach 1:
The patent applies preliminary action by performing protecting group removal and salt formation steps before the final coupling reaction. Specifically, the fatty acid protecting groups are removed in step a), and the amine is converted to its methanesulfonic acid salt in step b), which prevents side reactions during the subsequent coupling reaction in step c), thereby increasing yield and reducing by-products
Solution Approach 2:
The patent employs parameter changes by optimizing reaction conditions including using specific bases (triethylamine or N-methylmorpholine), controlling reaction temperatures (0°C to room temperature), selecting appropriate solvents (dichloromethane, ethyl acetate, acetonitrile), and adjusting stoichiometry (1.1-5.0 equivalents of reagents), which collectively improve yield and minimize by-product formation
2Ease of manufacture
If previous synthetic strategies for producing S104 are used, then the cationic lipid can be produced, but the work-up procedures are inconvenient
Solution Approach 1:
The patent applies extraction by removing the methanesulfonic acid salt forming step from the main reaction sequence and performing it separately in step b). This allows for easier separation and purification of intermediates, simplifying the overall work-up procedure while maintaining high synthetic efficiency
Solution Approach 2:
The patent segments the synthesis into four distinct steps with isolated work-up procedures. Each step produces a discrete intermediate that can be independently purified, avoiding the need for complex multi-step purification procedures and improving ease of manufacture
3Productivity
If viral transfection systems are used, then high transfection efficiency is achieved, but safety is reduced and preparation is complicated and expensive
Solution Approach 1:
The patent optimizes the physical and chemical parameters of the cationic lipid including the chain length (n=8-16), the protecting groups, and the salt form, to achieve high transfection efficiency comparable to viral systems while maintaining simplicity and safety in preparation
Solution Approach 2:
The patent employs a non-viral cationic lipid system that can be synthesized and stored, replacing complex viral systems that require complicated preparation procedures. The cationic lipid provides a stable, reusable alternative that eliminates the need for complex viral vector preparation while maintaining effective transfection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves yields of at least 70% with purity between 95% and 99.9% without chromatography purification, significantly improving the efficiency and reducing impurities like compound VIII to less than 500 ppm.
Implementation Method 1
reacting a compound of Formula II with a compound of Formula III to form a compound of Formula IV
Implementation Method 2
followed by treatment with methane sulfonic acid, to form a compound of Formula IV
Implementation Method 3
reacting a compound of Formula VI under coupling conditions with 2-(dimethylamino)ethanethiol HCl, followed by treatment with oxalic acid, to form a compound of Formula VII
Implementation Method 4
reacting the compound of Formula VII with a base to produce a compound of Formula I
Data Source
AI summary
The present application provides processes for synthesizing lipids of Formula I useful in the synthesis of fat-soluble compounds for targeting and enhancing activity of therapeutic molecules, including siRNA.